Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2018        Go!    
 
 
June 23, Saturday 2018 9:41 AM       

       HEADLINES: 12-yr-old boy dies after Rambutan chokes his throat                                              Carnatic musician Alleppey Sreekumar is no more                                              Shobhana George Khadi Board vice-president                                              Death of foreign woman at Kovalam: Husband seeks CBI inquiry                                              Ganesh can be in soup if house woman sticks to statement                                              Congress' Saifuddin Soz backs Musharraf's remark on Kashmiris                                              GST brought positive changes in Indian economy: PM Modi                                              2 terrorists killed in Anantnag encounter                                              President Kovind highlights importance of South-South cooperation                                              India, Cuba to enhance cooperation in various fields                                              Radicals will soon be central to Pak democracy debate                                              FIFA WC: Musa helps Nigeria beat Iceland 2-0                                              FIFA WC: Shaqiri's last-minute stunner earns Switzerland 2-1 win over Serbia                                              Kaumudi Facebook
       SCI&TECH Next Article: Here is how you can travel smart using these apps!  
       A new ray of hope for breast cancer patients!
 
         Posted on :23:35:15 Mar 22, 2018
   
A A
       Last edited on:23:35:15 Mar 22, 2018
         Tags: Three-part molecule, Breast cancer patients
 

WASHINGTON DC: A new ray of hope has been found for breast cancer patients.

A newly designed three-part molecule could be the one answer patients with a certain form of breast cancer are looking for, according to a study conducted by the Medical College of Georgia at Augusta University.

This chimera, created by a team at the Georgia Cancer Center, has the ability to simultaneously decrease the expression of three growth factors that are over-expressed in some cancers.

The growth factors are human epidermal growth factor receptor 2 (HER2), human epidermal growth factor receptor 3 (HER3), and epidermal growth factor receptor (EGFR).

The new chimera interferes with HER2 and HER3 signaling and ultimately leads to cancer cell death.

"When HER2 is expressed in a cell, you'll usually find high expression of HER3, too," said researcher Hongyan Liu.

Extensive studies have found that 20-30 percent of breast cancers are characterized by over-expression of HER2, which makes the cancer cells grow and divide faster, leading to a cancer that's more aggressive and more likely to be resistant to the standard of care.

Patients with this type of breast cancer tend to have a poorer prognosis. "As a bioengineer, I am developing the materials for cancer-targeted treatment," Liu said.

"I have experience building multifunctional chimeras to target different types of genes associated with cancer cells."

Liu and her team created their molecule to target HER family receptors EGFR, HER2, and HER3 all at once, since it is well-known that another HER family member can compensate for one that is blocked by a drug having a single target.

Each component of this tripartite molecule has potent anti-tumor activity. The molecule was designed such that the EGFR-targeting component is sandwiched between the HER2- and HER3-targeting components in what is known as a HER2 aptamer-EGFR siRNA-HER3 aptamer chimera.

This construction enables the EGFR component to reach its target within HER2- and HER3-expressing cells. Compared to individual components, the chimera is large enough to avoid renal depletion, resulting in a prolonged circulation time and increased efficiency.

The newly crafted molecule is non-toxic, simple to produce, and cost-effective compared to the production of alternate treatment strategies, such as antibodies and small molecule inhibitors.

Liu's ongoing studies are testing the ability of the three-in-one chimera to treat breast cancers that are resistant to Herceptin, a drug that targets HER2.

This work is being done in collaboration with Dr. Hasan Korkaya who has developed drug-resistant cell lines, and with breast cancer clinicians.

"We need to prove that this molecule will work on Herceptin-resistant breast cancer patients," Liu said.

Since other cancers, such as lung and head and neck, proliferate due to HER family over-expression, Liu anticipates that the chimera's utility will not be limited to breast cancers alone.

The findings from this study are published in the publication Molecular Therapy: Nucleic Acids.

A A
       SCI&TECH
Next Article: Here is how you can travel smart using these apps!
 
 
SCI&TECH HEADLINES
Yoga helps against non-communicable diseases: WHO  
Spironolactone can help prevent acne: Study  
Older Amazonian forests help regulate global climate  
Goal conflict linked to depressive symptoms  
A new world: Top 10 new species for 2018  
Beat the risk of frailty with healthy heart  
Twitter to hide trolls that hurl abuse: Twitter CEO  
Fortnite is finally coming to Android  
This test could detect signs of pancreatic cancer  
Aliens exist but may be in parallel Universe: Study  
This is your heart on nitric oxide  
Is your kid's heart clock ticking right?  
Do at-risk adolescents show depressive symptoms on social media?  
NASA launches Insight spacecraft to Mars for deepest dig yet  
Daily intake of this drug can cause certain cancers in men  
A new weapon against epilepsy  
Hail stone weighing three kg sign of climate change: Expert  
PMSing? Could be because of alcohol!  
Social media firms given a week to better protect kids  
The stronger you are, the healthier your brain is  
NASA may soon identify 2,400 alien planets  
What triggers depression among adults?  
Turn your hobbies into part-time job opportunities with these apps  
Apple launches special RED Edition for iPhone 8, 8 Plus  
Humanity‚Äôs first flight to Sun to launch in July: NASA  
 
Should Yoga be made compulsory in all schools?
Yes
 
No
 
No opinion
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy